Biological markers: Tailoring treatment and trials to prognosis

Nature Reviews Clinical Oncology

Volumn 10, Issue 8, 2013, Pages 429-430

  Kerr, David J ^a   Shi, Yuankai ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CANCER THERAPY; CLINICAL OBSERVATION; COLON CANCER; COLORECTAL CANCER; DISEASE FREE SURVIVAL; GENE EXPRESSION; HIGH RISK PATIENT; HUMAN; LOW RISK POPULATION; MISMATCH REPAIR; OVERALL SURVIVAL; PATIENT SELECTION; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; SHORT SURVEY; TREATMENT OUTCOME;

EID: 84881474134     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2013.97     Document Type: Short Survey

References (10)

1. Schmoll, H. J. et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann. Oncol. 23, 2479-2516 (2012
2. La Thangue, N. B. & Kerr, D. J. Predictive biomarkers: A paradigm shift towards personalized cancer medicine. Nat. Rev. Clin. Oncol. 8, 587-596 (2011
3. Hutchins, G. et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J. Clin. Oncol. 29, 1261-1270 (2011
4. Salazar, R. et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J. Clin. Oncol. 1, 17-24 (2011
5. Gray, R. G. et al. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J. Clin. Oncol. 29, 4611-4619 (2011
6. Huijbers, A. et al. The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: Validation in the VICTOR trial. Ann. Oncol. 24, 179-185 (2013
7. Domingo, E. et al. Use of multivariate analysis to suggest a new molecular classification of colorectal cancer. J. Pathol. 229, 441-448 (2013
8. Kerr, D. J. & Midgley, R. Defective mismatch repair in colon cancer: A prognostic or predictive biomarker? J. Clin. Oncol. 28, 3210-3212 (2010
9. Peto, R. et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br. J. Cancer 34, 585-612 (1976
10. Van Cutsem, E. et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC 3. J. Clin. Oncol. 27, 3117-3125 (2009)